Form 4: Werewolf Therapeutics Director Sells Shares Under 10b5-1 Plan

Luke Evnin, a director at Werewolf Therapeutics, sold 137,041 shares of common stock across four transactions in November 2025, pursuant to a pre-established 10b5-1 plan.

Summary

• Luke Evnin, a director of Werewolf Therapeutics, Inc. (HOWL), reported the sale of 137,041 shares of common stock.
• The sales occurred over four separate transactions between November 7, 2025, and November 12, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• The shares were sold at weighted average prices ranging from $1.09 to $1.18 per share.
• Following these transactions, the indirect beneficial ownership attributed to Mr. Evnin decreased from 3,743,524 shares to 3,650,433 shares.
• The sales were conducted by various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P., where Mr. Evnin holds management roles.

Sentiment

Score: 4

Explanation: While the sales were pre-planned under a 10b5-1 plan, director selling, even if scheduled, can still be perceived as a slightly negative signal by the market, especially given the relatively low share prices. However, the pre-planned nature mitigates a strong negative interpretation.

Positives

• Transactions were executed under a Rule 10b5-1 plan, indicating pre-scheduled sales rather than a reaction to recent non-public information.

Negatives

• A director, through associated entities, sold a significant number of shares (137,041 shares).
• The sales occurred at relatively low prices, ranging from $1.09 to $1.18 per share.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted negatively by the market, potentially signaling a lack of confidence or a need for liquidity.

Future Outlook

na

Industry Context

This Form 4 filing reports routine insider selling under a pre-arranged plan, which is common across various industries, including biotechnology, for liquidity or portfolio rebalancing purposes by executives and directors.

Corporate Governance

Related Party Transactions

• The sales were conducted by various MPM entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.) where Luke Evnin holds management roles, making these related party transactions.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, could be interpreted as a slight negative signal, potentially influencing investor sentiment and the stock price.

Key Dates

Recommendation

The filing reports routine insider selling by a director under a pre-established 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-planned nature reduces its immediate bearish implications. There is no new fundamental information about the company's operations or future prospects in this filing to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational updates.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Selling, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Director Transaction, Biotechnology, Pharmaceuticals